
Hyaluronidase is an enzyme that breaks down hyaluronic acid. In aesthetic medicine, it may be used to reduce or dissolve dermal filler made from hyaluronic acid, but it does not dissolve every type of filler.
It is also not automatically the right treatment for every lump, swelling, asymmetry or unwanted change after filler. The product that was injected, where it is located and the likely cause of the problem all matter before hyaluronidase is considered.
If you are still researching dermal fillers more generally, see our guide to fillers.

Hyaluronidase is an enzyme that acts on hyaluronic acid. Hyaluronic acid is naturally present in the body and is also the main material used in many temporary dermal fillers.
Hyaluronic acid used in fillers is modified and cross-linked so that it remains in the tissue for longer. Different filler formulations can therefore respond differently when exposed to hyaluronidase.
This means hyaluronidase does not act on the general category of "filler". It acts on hyaluronic acid. Knowing what product was previously injected is therefore important.
For more detail about this filler material specifically, see what hyaluronic acid fillers are.
Hyaluronidase is the active enzyme. Hyalase is a UK medicine containing hyaluronidase.
Hyalase 1500 I.U. contains 1,500 international units of hyaluronidase and is a prescription-only medicine in the UK.
Its authorised medical uses include helping injected substances spread through tissue and promoting the absorption of excess fluid or blood in tissue. Dissolving cosmetic dermal filler is not one of its authorised indications.
Yes. Using hyaluronidase to dissolve dermal filler is an off-label use in the UK.
Off-label means a medicine is being used for a purpose outside its authorised indications. It does not by itself mean that the use is inappropriate, but the reason for using the medicine, expected benefit, limitations and relevant risks should be considered in the individual clinical situation.
Hyaluronidase can break down hyaluronic acid filler. It does not work as a universal dissolving agent for fillers made from other materials.
These contain the material on which hyaluronidase acts. How much a particular filler changes after treatment can vary according to the formulation, amount of filler, where it sits in the tissue and how the enzyme reaches it.
Fillers based on materials such as calcium hydroxylapatite or poly-L-lactic acid are not broken down by hyaluronidase in the same way. Hyaluronidase should therefore not be presented as an antidote for every injectable filler product.
If the product is unknown, this uncertainty matters. The original treatment record, product information from the previous clinic and further assessment may help establish what is likely to be present.
The appearance of a lump, swelling or area of asymmetry alone does not reliably confirm which filler material was injected.
Not every unwanted change after dermal filler is caused by hyaluronic acid filler that needs to be dissolved.
A visible or palpable change may relate to filler position or amount, but other explanations can include temporary swelling, inflammation or another filler-related problem. Previous treatments in the same area can make the assessment more complex.
Further assessment is particularly important when:
the previous filler product is unknown;
it is unclear what is causing the problem;
several treatments have been performed in the same area;
the injected material may not be hyaluronic acid;
there are signs that the issue could be a complication rather than an elective cosmetic correction.
The aim is to establish what is actually being treated before assuming that additional hyaluronidase is the answer.
A practitioner may aim to reduce only part of an unwanted hyaluronic acid filler result rather than remove as much material as possible. However, this should not be understood as selecting an exact percentage of filler to dissolve.
Hyaluronidase spreads through the treated tissue and different cross-linked hyaluronic acid fillers may respond differently. The position and amount of filler also affect how predictable a limited correction can be.
A treatment can therefore be targeted, but the cosmetic outcome cannot be controlled to an exact percentage or millimetre.
Hyaluronidase can start acting on hyaluronic acid after it is administered, but the visible appearance immediately afterwards does not necessarily show the final effect.
The injection itself can temporarily alter the area through swelling, tenderness or other local reactions. This can make early visual assessment misleading.
If a concern remains, further assessment may be needed before deciding whether additional treatment is appropriate. More hyaluronidase is not automatically the correct next step simply because the area does not yet look as expected.
Injection into an area can be followed by local reactions such as swelling, tenderness or bruising. These reactions can also make the cosmetic appearance difficult to judge immediately afterwards.
Contact the treating clinic if symptoms are unexpectedly severe, clearly worsening or different from what you were told to expect.
Allergic reactions to hyaluronidase can occur. Severe allergic reactions, including anaphylaxis, have been reported rarely.
Relevant allergies and previous reactions to medicines should therefore be discussed before treatment. Symptoms of a severe acute allergic reaction require urgent medical attention.
Hyaluronidase should not be presented as an exact cosmetic eraser. Some filler may remain, and the treated area may look different once filler volume has been reduced.
Temporary swelling can also affect the first assessment of the result.
Hyaluronidase acts on hyaluronic acid and does not simply recognise only the hyaluronic acid that came from dermal filler.
This is another reason why the treatment should be targeted and medically assessed rather than described as precisely removing only a selected amount of filler.
Hyaluronidase is a prescription-only medicine in the UK. Its use for dissolving cosmetic dermal filler is outside the authorised indications for Hyalase and is therefore off-label.
A practitioner should be able to explain why it is being considered and which risks, limitations and alternatives are relevant.
Sudden visual disturbance, severe or rapidly increasing pain, or unusual pale, grey or mottled skin after dermal filler should not be treated as a routine cosmetic correction.
These symptoms require urgent professional assessment rather than trying to determine for yourself whether hyaluronidase is needed.
Hyaluronidase may be discussed for a planned correction of unwanted hyaluronic acid filler, but it can also have a role in the management of certain complications involving hyaluronic acid filler. These are not the same clinical situation.
An elective correction allows time to assess the filler, the reason for changing it and the desired outcome. A suspected vascular complication after filler requires prompt professional assessment and should not be approached as routine filler dissolving.
For a broader explanation of warning signs and different filler problems, see filler complications.
Ultrasound can help a practitioner visualise previously injected filler and surrounding structures. This may be useful when the position of the filler is uncertain or the treatment history is more complex.
It can be particularly relevant when several previous injections have been performed in the same area, the location or depth of the material is unclear, or a more targeted assessment is needed.
Ultrasound is not automatically necessary before every use of hyaluronidase. Whether it adds useful information depends on the treatment history, area being assessed and the clinical question that needs to be answered.
Learn what filler migration means, how it can differ from normal swelling or placement and why the type of filler matters when considering correction.
Read more about Filler migration.
Read about different reasons a lump may be noticed after filler and why the cause should be assessed before assuming it needs dissolving.
Read more about Filler lumps.
This page focuses on hyaluronidase itself: what the enzyme does, the filler material it can act on and the main limitations and medical considerations around its use.
If you are considering an elective correction and want to understand how the assessment and treatment process works, continue to our guide to dissolving filler with hyaluronidase.
Treatment is not automatically necessary simply because you are dissatisfied with an area. Depending on what is causing the concern, further assessment or allowing more time may also be discussed.








Hyaluronidase is an enzyme that breaks down hyaluronic acid. In aesthetic medicine it may be used to reduce or dissolve dermal filler made from hyaluronic acid.
Hyalase is a UK prescription-only medicine containing the active ingredient hyaluronidase. Hyaluronidase is the enzyme; Hyalase is the medicine containing it.
Not exactly. Hyaluronidase is the active ingredient, while Hyalase is a medicine containing hyaluronidase.
No. Hyaluronidase acts on hyaluronic acid filler. Fillers made from other materials are not broken down by the enzyme in the same way.
A limited correction may be attempted with hyaluronic acid filler, but an exact percentage cannot be selected in advance. The effect depends on factors including the filler formulation, amount and location.
Hyaluronidase can begin acting after it is administered, but the visible result should not necessarily be judged immediately because swelling and other temporary injection reactions can alter the appearance.
Further assessment is important if the product is unknown. Previous treatment records may help identify it, and imaging such as ultrasound may be useful in selected situations.
Yes. Dissolving cosmetic dermal filler is not an authorised indication for Hyalase in the UK, so its use for this purpose is off-label.
No. Hyaluronidase acts on hyaluronic acid and does not simply distinguish between hyaluronic acid from filler and hyaluronic acid naturally present in the treated tissue.
It can have a role in certain complications involving hyaluronic acid filler. A suspected complication requires professional assessment because emergency management is different from a planned cosmetic filler correction.
Search, compare and book a injectable or filler treatment
Injectablesbooking.co.uk part of Halftien BV
info@injectablesbooking.co.uk
KVK: 81484879
BTW: NL862111808B01